Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Protalix BioTherapeutics, Inc. | Director | Stock Options (Right to Buy) | 85.7K | Sep 14, 2023 | Direct | ||
F-star Therapeutics, Inc. | PRESIDENT AND CEO, Director | Common Stock | 0 | $7.12 | Mar 8, 2023 | Direct | |
F-star Therapeutics, Inc. | PRESIDENT AND CEO, Director | Stock Option (right to buy) | 0 | Mar 8, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
PLX | Protalix BioTherapeutics, Inc. | Sep 14, 2023 | 1 | $0 | 4 | Sep 15, 2023 | Director |
PLX | Protalix BioTherapeutics, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 15, 2023 | Director |
FSTX | F-star Therapeutics, Inc. | Mar 8, 2023 | 5 | -$3M | 4 | Mar 9, 2023 | PRESIDENT AND CEO, Director |
FSTX | F-star Therapeutics, Inc. | Jul 29, 2022 | 3 | $28.7K | 4 | Aug 2, 2022 | President and CEO, Director |
FSTX | F-star Therapeutics, Inc. | Mar 31, 2022 | 1 | $0 | 4 | Apr 4, 2022 | President and CEO, Director |
FSTX | F-star Therapeutics, Inc. | Jan 9, 2022 | 1 | $0 | 4 | Jan 11, 2022 | President and CEO, Director |